ClinicalTrials.gg
CompletedNCT06792136Updated Jul 8, 2026

A Study of ONO-1110 in Patients With Major Depressive Disorder

A Phase 2 interventional study of ONO-1110 and Placebo in Major Depressive Disorder (MDD, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 29 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies in Depressive Disorder, Major with a site in Japan — 3 open to participants now, 3 under way, 3 of them phase 3. Depressive Disorder, Major · Japan.

Enrollment
33rd of 46
103 · median 246
Started
2025
with 1 other
Phase 2
12 of 47
none open now
Registered
44th of 47
by date

Among the 47 studies in Depressive Disorder, Major with a site in Japan, this one is the 33rd largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 in phase 2, and was the 44th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

3 of the 47 studies in Depressive Disorder, Major with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Depressive Disorder, Major with a site in Japan, or all of them as a file.
02

Study summary

To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Major Depressive Disorder

03

Conditions studied

  • Major Depressive Disorder (MDD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese (sex not specified)
  2. Participants who, in the opinion of the principal (or sub-investigator), are capable of understanding the content of the clinical trial and complying with its requirements
  3. Participants diagnosed with major depressive disorder based on (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision) criteria, as determined through an interview using the M.I.N.I. (Mini-international neuropsychiatric interview)
  4. Outpatients
  5. Participants whose current depressive episode has lasted for at least 2 months but no more than 12 months
  6. Participants with a HAM-D17 (Hamilton depression rating scale 17 items) total score of 18 or higher and a CGI-S (Clinical global impression-Improvement) score of 4 or higher

Exclusion criteria

Exclusion Criteria:

  1. Participants with a current or past history of psychiatric or neurological disorders that meet any of the following criteria:

    • Participants with a comorbid psychiatric disorder other than major depressive disorder as defined by (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision) (assessed using the M.I.N.I.(Mini-international neuropsychiatric interview))
    • Participants with major depressive disorder with mixed features, psychotic features, or catatonia as defined by DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision)
    • Participants with a current or past history of schizophrenia or other psychotic disorders as defined by DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision)
    • Participants with neurodevelopmental disorders or personality disorders as defined by DSM-5-TR (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision)
    • Participants with a current or past history of neurological disorders (including epilepsy)
    • Participants with neurodegenerative diseases (such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.)
  2. Participants who, in the opinion of the principal (or sub-investigator), have not responded to at least two different antidepressants, each administered at an adequate dose for at least 6 weeks, during the current or past depressive episode.
  3. Participants who have used adjunctive treatments such as lithium, triiodothyronine/thyroxine, lamotrigine, valproate, carbamazepine, or atypical antipsychotics, or who have used combination therapy with antidepressants for the current depressive episode.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    ONO-1110

    Drug: ONO-1110 · Drug: Placebo

  • Placebo comparator
    Placebo

    Drug: ONO-1110 · Drug: Placebo

Interventions

  • ONO-1110 tablets once a day

  • DrugPlacebo

    Placebo tablets once daily

06

What researchers measure

Primary outcomes

  1. Change in HAM-D17(Hamilton depression rating scale 17 items) total score from baseline to Week 8 of the treatment period

    Time frame: Up to 16 weeks

Secondary outcomes

  1. The transition of HAM-D17(Hamilton depression rating scale 17 items) total score from baseline to Week 8 of the treatment period

    Time frame: Up to 16 weeks

  2. Responder rates of HAM-D17(Hamilton depression rating scale 17 items) total score at 1, 2, 4, 6, and 8 weeks of the treatment period

    Responder is defined as a reduction of 50% or more in HAM-D17(Hamilton depression rating scale 17 items) total score from baseline

    Time frame: Up to 16 weeks

  3. Remitted patient rates of HAM-D17(Hamilton depression rating scale 17 items) score at 1, 2, 4, 6, and 8 weeks of the treatment period

    Remitted patient is defined as a total HAM-D17(Hamilton depression rating scale 17 items) total score of 7 or less.

    Time frame: Up to 16 weeks

  4. Change in the total MADRS(Montgomery-Åsberg depression rating scale) score from baseline to Week 8 of the treatment period

    Time frame: Up to 16 weeks

  5. Transition of HAM-A(Hamilton Anxiety Scale) total score from baseline to Week 8 of the treatment period

    Time frame: Up to 16 weeks

  6. Transition of CGI-S(Clinical Global Impression of illness Severity) score from baseline to Week 8 of the treatment period

    Time frame: Up to 16 weeks

  7. Transition of QIDS-J(Quick Inventory of Depressive Symptomatology) total score from baseline to Week 8 of the treatment period

    Time frame: Up to 16 weeks

  8. Transition of CGI-I(Clinical Global Impression of Impression Important) score from baseline to Week 8 of the treatment period

    Time frame: Up to 16 weeks

  9. Plasma ONO-1110 concentrations

    Time frame: Up to 16 weeks

  10. Adverse Events

    Time frame: Up to 16 weeks

07

Study locations

29 sites
  • AK Clinic
    Fukuoka, Japan
  • Hiro Mental Clinic
    Fukuoka, Japan
  • Hirota Clinic
    Fukuoka, Japan
  • Kokorono Clinic Hirao
    Fukuoka, Japan
  • Kokorono Clinic Iizuka
    Fukuoka, Japan
  • Kokura Mental Clinic
    Fukuoka, Japan
  • Mental Clinic Sakurazaka
    Fukuoka, Japan
  • Shinseikai Kaku Mental Clinic
    Fukuoka, Japan
  • Uematsu Mental Clinic
    Fukuoka, Japan
  • Ichikawa Clinic
    Gunma, Japan
  • Higashi-Sapporo Mental Clinic
    Hokkaido, Japan
  • Kawamura Mental Clinic
    Hokkaido, Japan
  • Minami1jo Mental Clinic
    Hokkaido, Japan
  • Sapporo Kobushi Clinic
    Hokkaido, Japan
  • Shimode Mental Clinic
    Hokkaido, Japan
  • Tatsuta Clinic
    Hyōgo, Japan
  • Kishiro Mental Clinic
    Kanagawa, Japan
  • Yutaka Clinic
    Kanagawa, Japan
  • Harai Clinic
    Tokyo, Japan
  • Iidabashi Mental Clinic
    Tokyo, Japan
  • Ikebukuro Olive Mental Clinic
    Tokyo, Japan
  • Kitaikebukuro Kokoro No Clinic
    Tokyo, Japan
  • Maynds Tower Mental Clinic
    Tokyo, Japan
  • Meguroeki Higashiguchi Mental Clinic
    Tokyo, Japan
  • Monzen-nakacho Mental Clinic
    Tokyo, Japan
  • Niseikai Murakami Iin
    Tokyo, Japan
  • Nishi-Shinjuku Concieria Clinic
    Tokyo, Japan
  • Sakurazaka Clinic SophyAnce
    Tokyo, Japan
  • Sangenjaya Nakamura Mental Clinic
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Apr 2026, 14 months.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 14 months is below that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2025
First posted
Jan 24, 2025
StartActual
Jan 16, 2025
Primary completionActual
Apr 9, 2026
CompletionActual
Apr 9, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06792136
Responsible party
Sponsor
First posted
Jan 24, 2025
Start date
Jan 16, 2025
Primary completion
Apr 9, 2026
Completion
Apr 9, 2026
Last update
Jul 8, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ONO-1110

Start the discussion